International trade and protection of intellectual property; TRIPS Waiver; compulsory licensing and other IP issues in multiple countries. Advocate on drug pricing proposals, including reconciliation legislation, and expanding access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Engage on pharmaceutical policy as it relates to payments under the 340B program. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments for COVID-19 (2019 Novel Coronavirus), including: manufacturing, clinical trials, reimbursement and coverage of Veklury (remdesivir). Reauthorization of the Prescription Drug User Fee Act and related issues. Advocate on drug pricing proposals, including reconciliation legislation. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and Value-Based Purchasing arrangements including changes to best price. Issues related to pharmaceuticals and intellectual property protection including technology transfer, patent rights and funding. Funding for Hepatitis C, HIV, oncology, and public health activities via appropriations. Advocate on drug pricing proposals, including reconciliation legislation. Legislative and regulatory proposals to change international and domestic corporate tax law and policy, including reconciliation legislation.
TRD - Trade (domestic/foreign) HCR - Health Issues MMM - Medicare/Medicaid CPT - Copyright/Patent/Trademark BUD - Budget/Appropriations TAX - Taxation/Internal Revenue Code
24 - Commerce, Dept of (DOC) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 16 - Natl Security Council (NSC) 113 - Patent & Trademark Office (PTO) 1 - SENATE 39 - State, Dept of (DOS) 22 - U.S. Trade Representative (USTR) 134 - Centers For Disease Control & Prevention (CDC) 136 - Centers For Medicare and Medicaid Services (CMS) 24 - Commerce, Dept of (DOC) 135 - Food & Drug Administration (FDA) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 139 - Natl Institutes of Health (NIH) 13 - Office of the Vice President of the United States 1 - SENATE 39 - State, Dept of (DOS) 22 - U.S. Trade Representative (USTR) 12 - White House Office 136 - Centers For Medicare and Medicaid Services (CMS) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 18 - Office of Management & Budget (OMB) 1 - SENATE 12 - White House Office 24 - Commerce, Dept of (DOC) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 113 - Patent & Trademark Office (PTO) 1 - SENATE 22 - U.S. Trade Representative (USTR) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 24 - Commerce, Dept of (DOC) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 41 - Treasury, Dept of
GILEAD SCIENCES, INC.
333 LAKESIDE DRIVE, FOSTER CITY, CA, 94404, US
DAVID PULLIAM CHARLES M. CLAPTON MICHAEL D BOYD GRACE RODDEN DAVID PULLIAM CHARLES M. CLAPTON MICHAEL D BOYD ANNA GRIFFIN JENNIFER NIETO CAREY GRACE RODDEN BILL BODE DAVID PULLIAM CHARLES M. CLAPTON MICHAEL D BOYD ANNA GRIFFIN JENNIFER NIETO CAREY GRACE RODDEN BILL BODE DAVID PULLIAM CHARLES M. CLAPTON JENNIFER NIETO CAREY BILL BODE GRACE RODDEN DAVID PULLIAM CHARLES M. CLAPTON JENNIFER NIETO CAREY GRACE RODDEN BILL BODE CHARLES M. CLAPTON DAVID PULLIAM